Literature DB >> 11358005

An immunohistochemical analysis of cyclin D1, p53, and p21waf1/cip1 proteins in tumors originating from the follicular epithelium of the thyroid gland.

A Goto1, A Sakamoto, R Machinami.   

Abstract

This study aimed at clarifying the factors closely related to the tumor progression of thyroid neoplasms. We examined the immunoreactivity of cyclin D1, p53, and p21waf1/cip1 proteins in 179 thyroid tumors originating from the follicular epithelium using an immunohistochemical technique. Cyclin D1 positivity was frequent in well-differentiated thyroid carcinomas (39/122 cases), but it was rarely seen in follicular adenomas (1/33 cases), (p < 0.05). Positivity for p53 was more frequent in poorly differentiated carcinomas (7/19 cases) and undifferentiated carcinomas (4/5 cases) than in well-differentiated carcinomas (14/122 cases) (p < 0,05, respectively). P21waf1/cip1 positivity was more frequent in well-differentiated thyroid carcinomas (43/122 cases) than in follicular adenomas (4/33 cases) (p < 0.05). Regarding the relationships of these proteins, co-positivity for cyclin D1 and p53 was observed more often in poorly differentiated carcinomas (5/7 cases) than in well-differentiated carcinomas (7/39 cases) (p < 0.05). Most cases with cyclin D1 positivity did not show p21waf1/cip1 expression in poorly differentiated carcinomas (6/7 cases). Three cases examined showed co-positivity of p53 and p21waf1/cip1. Our results suggest that cyclin D1 is invoved in thyroid oncogenesis. Moreover, p53 might be closely related to the development of poorly differentiated carcinomas and undifferentiated carcinomas originating from well-differentiated carcinomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358005     DOI: 10.1078/0344-0338-00037

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

1.  Low level of cyclin D1 protein expression in thyroid microcarcinomas from an autopsy series.

Authors:  Gabor Laszlo Kovacs; Eva Stelkovics; Laszlo Krenacs; Gabor Gonda; Miklos Goth; Laszlo Kovacs; Zoltan Gorombey; Erika Hubina; Istvan Szabolcs
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

Review 2.  Occult thyroid carcinoma.

Authors:  J Boucek; J Kastner; J Skrivan; E Grosso; B Gibelli; G Giugliano; J Betka
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

3.  Expression of p21cip1, p27kip1, and p16INk4a cyclin-dependent kinase inhibitors in papillary thyroid carcinoma: correlation with clinicopathological factors.

Authors:  Carles Zafon; Gabriel Obiols; Josep Castellví; Santiago Ramon y Cajal; Juan Antonio Baena; Jordi Mesa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.

Authors:  Young Joo Park; Soo Heon Kwak; Dong Chul Kim; Haeryoung Kim; Gheeyoung Choe; Do Joon Park; Hak Chul Jang; Seong Hoe Park; Bo Youn Cho; So Yeon Park
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

5.  Gene expression profile in functioning and non-functioning nodules of autonomous multinodular goiter from an area of iodine deficiency: unexpected common characteristics between the two entities.

Authors:  P Agretti; G De Marco; E Ferrarini; C Di Cosmo; L Montanelli; B Bagattini; L Chiovato; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2021-08-17       Impact factor: 4.256

6.  Expression of cdc25A and cdc25B proteins in thyroid neoplasms.

Authors:  Y Ito; H Yoshida; K Nakano; K Kobayashi; T Yokozawa; K Hirai; F Matsuzuka; N Matsuura; K Kakudo; K Kuma; A Miyauchi
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.